Back to Cardiology
Cardiologyv2010Evidence-Based

CRUSADE Score for Post-MI Bleeding Risk

Risk stratifies patients with NSTEMI undergoing anticoagulation to determine their risk of major bleeding during hospitalization

Clinical Input Parameters

percentage
Range: 15 — 55 percentage
mL/min
Range: 5 — 200 mL/min
bpm
Range: 30 — 200 bpm
sex
presence
presence
presence
mmHg
Range: 60 — 250 mmHg
Clinical Assessment
Awaiting Parameters
crusade score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The CRUSADE Score for Post-MI Bleeding Risk is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within cardiology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Sum of weighted points: Hematocrit + Creatinine Clearance + Heart Rate + Sex + CHF Signs + Diabetes + Vascular Disease + Systolic BP

Clinical Pearls & Practice Notes

  • Developed and validated in NSTEMI patients undergoing antithrombotic therapy
  • Major bleeding defined as: hematocrit drop ≥12%, RBC transfusion (if baseline Hct ≥28%), or RBC transfusion with witnessed bleeding (if baseline Hct <28%)
  • Score ranges from 1-100 points with higher scores indicating greater bleeding risk
  • Validated in both NSTEMI and STEMI patients
  • Should be used in conjunction with ischemic risk assessment for optimal decision-making
  • Consider patient-specific factors and bleeding history not captured in the score
  • Useful for selecting appropriate antithrombotic regimens and monitoring intensity
  • Can guide duration of dual antiplatelet therapy
  • Female sex independently associated with increased bleeding risk

Evidence & Literature Citations

  1. Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation. 2009;119(14):1873-1882.
  2. Abu-Assi E, Raposeiras-Roubin S, Lear P, et al. The risk of bleeding according to the CRUSADE, ACUITY and HAS-BLED scores in acute coronary syndrome patients treated with prasugrel: insights from a four-year registry. Thromb Res. 2013;132(6):652-658.
  3. Ariza-Solé A, Sánchez-Elvira G, Sánchez-Salado JC, et al. CRUSADE bleeding score validation for ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Thromb Res. 2013;132(6):652-658.

Score Interpretation Ranges

Very Low Risk1 – 20 pts

Very low bleeding risk

Low Risk21 – 30 pts

Low bleeding risk

Moderate Risk31 – 40 pts

Moderate bleeding risk

High Risk41 – 50 pts

High bleeding risk

Very High Risk51 – 100 pts

Very high bleeding risk

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.